The Year in Lipid Disorders:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Oxford
Clinical Pub.
2010
|
| Schriftenreihe: | Year in Lipid Disorders
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 Volltext |
| Beschreibung: | Contents; Editors; Contributors; Part 1: Clinical aspects ofatherosclerotic disease; Chapter 1: Proprotein convertase subtilisin/kexin type 9 (PCSK9): molecular function and impact of its mutations and polymorphisms on cholesterol levels and related diseases; Chapter 2: Metabolic syndrome, diabetes and cardiovascular risk; Chapter 3: Diet and exercise in the prevention and treatment of diabetes and coronary heart disease; Chapter 4: Imaging developments in vascular disease; Part II: Lipids, lipoproteins and atherosclerosis Chapter 5: Ezetimibe: mechanism of action update and recent controversiesChapter 6: Oxidative stress, lipoprotein oxidation and atherosclerosis; Chapter 7: Updating the metabolism of apolipoprotein B-100- containing lipoproteins in dyslipidaemia; Chapter 8: Triglycerides and atherosclerosis; Part III: Prevention and treatment strategies; Chapter 9: JUPITER: the crossroads between statin therapy, inflammation and cardiovascular risk reduction; Chapter 10: New clinical trials of lipid regulatingagents; Chapter 11: Statin myopathy Chapter 12: Nuclear receptors (PPARs, LXRs and TRs) and their role in regulating lipid metabolismPart IV: Infection, inflammation and secondary causes of atherosclerosis; Chapter 13: Inflammation, inflammatory disease and coronary atherosclerosis; Chapter 14: Mechanisms of insulin resistance; Chapter 15: Haemostasis-dyslipidaemia interactions in coronary heart disease; Acronyms/abbreviations; Index of papers reviewed; General index Lipid disorders are among the primary risk factors in developing atherosclerosis and heart disease. Providing an up-to-date insight into the latest research into lipid disorders, and the implications of this research for daily clinical practice, this collection includes an overview of the latest developments in this complex field by reviewing the most significant papers published in the medical journals on lipid disorders over the last eighteen months Includes bibliographical references and indexes |
| Beschreibung: | 1 Online-Ressource (333 pages) |
| ISBN: | 1846920612 184692622X 9781846920615 9781846926228 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043161159 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151126s2010 |||| o||u| ||||||eng d | ||
| 020 | |a 1846920612 |c electronic bk. |9 1-84692-061-2 | ||
| 020 | |a 184692622X |9 1-84692-622-X | ||
| 020 | |a 9781846920615 |c electronic bk. |9 978-1-84692-061-5 | ||
| 020 | |a 9781846926228 |9 978-1-84692-622-8 | ||
| 035 | |a (OCoLC)693761617 | ||
| 035 | |a (DE-599)BVBBV043161159 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 616.3997 |2 22 | |
| 100 | 1 | |a Toth, Peter P. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a The Year in Lipid Disorders |
| 264 | 1 | |a Oxford |b Clinical Pub. |c 2010 | |
| 300 | |a 1 Online-Ressource (333 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Year in Lipid Disorders | |
| 500 | |a Contents; Editors; Contributors; Part 1: Clinical aspects ofatherosclerotic disease; Chapter 1: Proprotein convertase subtilisin/kexin type 9 (PCSK9): molecular function and impact of its mutations and polymorphisms on cholesterol levels and related diseases; Chapter 2: Metabolic syndrome, diabetes and cardiovascular risk; Chapter 3: Diet and exercise in the prevention and treatment of diabetes and coronary heart disease; Chapter 4: Imaging developments in vascular disease; Part II: Lipids, lipoproteins and atherosclerosis | ||
| 500 | |a Chapter 5: Ezetimibe: mechanism of action update and recent controversiesChapter 6: Oxidative stress, lipoprotein oxidation and atherosclerosis; Chapter 7: Updating the metabolism of apolipoprotein B-100- containing lipoproteins in dyslipidaemia; Chapter 8: Triglycerides and atherosclerosis; Part III: Prevention and treatment strategies; Chapter 9: JUPITER: the crossroads between statin therapy, inflammation and cardiovascular risk reduction; Chapter 10: New clinical trials of lipid regulatingagents; Chapter 11: Statin myopathy | ||
| 500 | |a Chapter 12: Nuclear receptors (PPARs, LXRs and TRs) and their role in regulating lipid metabolismPart IV: Infection, inflammation and secondary causes of atherosclerosis; Chapter 13: Inflammation, inflammatory disease and coronary atherosclerosis; Chapter 14: Mechanisms of insulin resistance; Chapter 15: Haemostasis-dyslipidaemia interactions in coronary heart disease; Acronyms/abbreviations; Index of papers reviewed; General index | ||
| 500 | |a Lipid disorders are among the primary risk factors in developing atherosclerosis and heart disease. Providing an up-to-date insight into the latest research into lipid disorders, and the implications of this research for daily clinical practice, this collection includes an overview of the latest developments in this complex field by reviewing the most significant papers published in the medical journals on lipid disorders over the last eighteen months | ||
| 500 | |a Includes bibliographical references and indexes | ||
| 650 | 7 | |a MEDICAL / Endocrinology & Metabolism |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Nutrition |2 bisacsh | |
| 650 | 7 | |a Lipidoses |2 fast | |
| 650 | 7 | |a Lipids / Research |2 fast | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Lipidoses | |
| 650 | 4 | |a Lipids |x Research | |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=343868 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028585350 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=343868 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=343868 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175631587475456 |
|---|---|
| any_adam_object | |
| author | Toth, Peter P. |
| author_facet | Toth, Peter P. |
| author_role | aut |
| author_sort | Toth, Peter P. |
| author_variant | p p t pp ppt |
| building | Verbundindex |
| bvnumber | BV043161159 |
| collection | ZDB-4-EBA |
| ctrlnum | (OCoLC)693761617 (DE-599)BVBBV043161159 |
| dewey-full | 616.3997 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.3997 |
| dewey-search | 616.3997 |
| dewey-sort | 3616.3997 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03767nmm a2200505zc 4500</leader><controlfield tag="001">BV043161159</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151126s2010 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1846920612</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">1-84692-061-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">184692622X</subfield><subfield code="9">1-84692-622-X</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781846920615</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-1-84692-061-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781846926228</subfield><subfield code="9">978-1-84692-622-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)693761617</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043161159</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.3997</subfield><subfield code="2">22</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Toth, Peter P.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The Year in Lipid Disorders</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford</subfield><subfield code="b">Clinical Pub.</subfield><subfield code="c">2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (333 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Year in Lipid Disorders</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Contents; Editors; Contributors; Part 1: Clinical aspects ofatherosclerotic disease; Chapter 1: Proprotein convertase subtilisin/kexin type 9 (PCSK9): molecular function and impact of its mutations and polymorphisms on cholesterol levels and related diseases; Chapter 2: Metabolic syndrome, diabetes and cardiovascular risk; Chapter 3: Diet and exercise in the prevention and treatment of diabetes and coronary heart disease; Chapter 4: Imaging developments in vascular disease; Part II: Lipids, lipoproteins and atherosclerosis</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Chapter 5: Ezetimibe: mechanism of action update and recent controversiesChapter 6: Oxidative stress, lipoprotein oxidation and atherosclerosis; Chapter 7: Updating the metabolism of apolipoprotein B-100- containing lipoproteins in dyslipidaemia; Chapter 8: Triglycerides and atherosclerosis; Part III: Prevention and treatment strategies; Chapter 9: JUPITER: the crossroads between statin therapy, inflammation and cardiovascular risk reduction; Chapter 10: New clinical trials of lipid regulatingagents; Chapter 11: Statin myopathy</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Chapter 12: Nuclear receptors (PPARs, LXRs and TRs) and their role in regulating lipid metabolismPart IV: Infection, inflammation and secondary causes of atherosclerosis; Chapter 13: Inflammation, inflammatory disease and coronary atherosclerosis; Chapter 14: Mechanisms of insulin resistance; Chapter 15: Haemostasis-dyslipidaemia interactions in coronary heart disease; Acronyms/abbreviations; Index of papers reviewed; General index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Lipid disorders are among the primary risk factors in developing atherosclerosis and heart disease. Providing an up-to-date insight into the latest research into lipid disorders, and the implications of this research for daily clinical practice, this collection includes an overview of the latest developments in this complex field by reviewing the most significant papers published in the medical journals on lipid disorders over the last eighteen months</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and indexes</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Endocrinology & Metabolism</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Nutrition</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lipidoses</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lipids / Research</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lipidoses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lipids</subfield><subfield code="x">Research</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=343868</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028585350</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=343868</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=343868</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043161159 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:19:22Z |
| institution | BVB |
| isbn | 1846920612 184692622X 9781846920615 9781846926228 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028585350 |
| oclc_num | 693761617 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 Online-Ressource (333 pages) |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | Clinical Pub. |
| record_format | marc |
| series2 | Year in Lipid Disorders |
| spelling | Toth, Peter P. Verfasser aut The Year in Lipid Disorders Oxford Clinical Pub. 2010 1 Online-Ressource (333 pages) txt rdacontent c rdamedia cr rdacarrier Year in Lipid Disorders Contents; Editors; Contributors; Part 1: Clinical aspects ofatherosclerotic disease; Chapter 1: Proprotein convertase subtilisin/kexin type 9 (PCSK9): molecular function and impact of its mutations and polymorphisms on cholesterol levels and related diseases; Chapter 2: Metabolic syndrome, diabetes and cardiovascular risk; Chapter 3: Diet and exercise in the prevention and treatment of diabetes and coronary heart disease; Chapter 4: Imaging developments in vascular disease; Part II: Lipids, lipoproteins and atherosclerosis Chapter 5: Ezetimibe: mechanism of action update and recent controversiesChapter 6: Oxidative stress, lipoprotein oxidation and atherosclerosis; Chapter 7: Updating the metabolism of apolipoprotein B-100- containing lipoproteins in dyslipidaemia; Chapter 8: Triglycerides and atherosclerosis; Part III: Prevention and treatment strategies; Chapter 9: JUPITER: the crossroads between statin therapy, inflammation and cardiovascular risk reduction; Chapter 10: New clinical trials of lipid regulatingagents; Chapter 11: Statin myopathy Chapter 12: Nuclear receptors (PPARs, LXRs and TRs) and their role in regulating lipid metabolismPart IV: Infection, inflammation and secondary causes of atherosclerosis; Chapter 13: Inflammation, inflammatory disease and coronary atherosclerosis; Chapter 14: Mechanisms of insulin resistance; Chapter 15: Haemostasis-dyslipidaemia interactions in coronary heart disease; Acronyms/abbreviations; Index of papers reviewed; General index Lipid disorders are among the primary risk factors in developing atherosclerosis and heart disease. Providing an up-to-date insight into the latest research into lipid disorders, and the implications of this research for daily clinical practice, this collection includes an overview of the latest developments in this complex field by reviewing the most significant papers published in the medical journals on lipid disorders over the last eighteen months Includes bibliographical references and indexes MEDICAL / Endocrinology & Metabolism bisacsh MEDICAL / Nutrition bisacsh Lipidoses fast Lipids / Research fast Medizin Lipidoses Lipids Research http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=343868 Aggregator Volltext |
| spellingShingle | Toth, Peter P. The Year in Lipid Disorders MEDICAL / Endocrinology & Metabolism bisacsh MEDICAL / Nutrition bisacsh Lipidoses fast Lipids / Research fast Medizin Lipidoses Lipids Research |
| title | The Year in Lipid Disorders |
| title_auth | The Year in Lipid Disorders |
| title_exact_search | The Year in Lipid Disorders |
| title_full | The Year in Lipid Disorders |
| title_fullStr | The Year in Lipid Disorders |
| title_full_unstemmed | The Year in Lipid Disorders |
| title_short | The Year in Lipid Disorders |
| title_sort | the year in lipid disorders |
| topic | MEDICAL / Endocrinology & Metabolism bisacsh MEDICAL / Nutrition bisacsh Lipidoses fast Lipids / Research fast Medizin Lipidoses Lipids Research |
| topic_facet | MEDICAL / Endocrinology & Metabolism MEDICAL / Nutrition Lipidoses Lipids / Research Medizin Lipids Research |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=343868 |
| work_keys_str_mv | AT tothpeterp theyearinlipiddisorders |